Immutep disclosed that an independent data monitoring committee recommended stopping its pivotal Phase 3 study of eftilagimod alfa (efti) combined with pembrolizumab for first‑line non‑small cell lung cancer due to futility. The Sydney‑based immunotherapy developer said it will wind down the study after the DMC review, surprising analysts given earlier promising Phase 2 signals in head‑and‑neck cohorts. Management warned investors the company will conduct a comprehensive data review to understand the failure. The outcome erased investor expectations for a chemo‑sparing LAG‑3‑based approach and triggered an immediate, sharp decline in Immutep’s share price, underscoring the high binary risk of late‑stage oncology trials.